Trials / Completed
CompletedNCT03198715
Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is determined that each dose is safe and tolerable, the next higher dose will be given to the next group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS1040b | DS-1040b in solution for intravenous infusion |
| DRUG | Placebo | Saline solution for intravenous infusion |
Timeline
- Start date
- 2017-07-30
- Primary completion
- 2020-01-19
- Completion
- 2020-01-19
- First posted
- 2017-06-26
- Last updated
- 2021-01-28
- Results posted
- 2021-01-28
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03198715. Inclusion in this directory is not an endorsement.